ロード中...
Present and Future of Efficacy Biomarkers in Immune Checkpoint Inhibitors of Small Cell Lung Cancer
Inhibitions of immune checkpoints, including programmed cell death 1-programmed cell death-ligand 1 (PD-1-PD-L1) axis, cytotoxic T lymphocyte associated antigen-4, are at the forefront of immunotherapy for small cell lung cancer. However, the survival benefits emerged after three to six months since...
保存先:
| 主要な著者: | , |
|---|---|
| フォーマット: | Artigo |
| 言語: | Chinês |
| 出版事項: |
Chinese Anti-Cancer Association; Chinese Antituberculosis Association
2020-10-01
|
| シリーズ: | Chinese Journal of Lung Cancer |
| 主題: | |
| オンライン･アクセス: | http://dx.doi.org/10.3779/j.issn.1009-3419.2020.101.42 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|